Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Sangamo Therapeutics's total assets was $59.97M at Mar 31, 2026. For fiscal 2025 it was $59.75M, down 41.2% from the year before. Over ten years it grew -12.1% a year on average. The highest annual figure on record is $938.55M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.75M | -41.2% |
| FY2024 | Dec 31, 2024 | $101.64M | -38.5% |
| FY2023 | Dec 31, 2023 | $165.32M | -70.6% |
| FY2022 | Dec 31, 2022 | $562.51M | -22.1% |
| FY2021 | Dec 31, 2021 | $721.92M | -23.1% |
| FY2020 | Dec 31, 2020 | $938.55M | +47.2% |
| FY2019 | Dec 31, 2019 | $637.52M | +8.0% |
| FY2018 | Dec 31, 2018 | $590.40M | +105.9% |
| FY2017 | Dec 31, 2017 | $286.74M | +81.6% |
| FY2016 | Dec 31, 2016 | $157.89M | -27.3% |
| FY2015 | Dec 31, 2015 | $217.24M | -10.7% |
| FY2014 | Dec 31, 2014 | $243.21M | +72.7% |
| FY2013 | Dec 31, 2013 | $140.84M | +70.6% |
| FY2012 | Dec 31, 2012 | $82.53M | -5.5% |
| FY2011 | Dec 31, 2011 | $87.34M | +38.6% |
| FY2010 | Dec 31, 2010 | $63.00M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $59.97M | -30.4% |
| Q4 FY2025 | Dec 31, 2025 | $59.75M | -41.2% |
| Q3 FY2025 | Sep 30, 2025 | $88.64M | -20.3% |
| Q2 FY2025 | Jun 30, 2025 | $97.56M | +4.9% |
| Q1 FY2025 | Mar 31, 2025 | $86.17M | -33.2% |
| Q4 FY2024 | Dec 31, 2024 | $101.64M | -38.5% |
| Q3 FY2024 | Sep 30, 2024 | $111.26M | -49.4% |
| Q2 FY2024 | Jun 30, 2024 | $93.01M | -71.4% |
| Q1 FY2024 | Mar 31, 2024 | $128.96M | -70.7% |
| Q4 FY2023 | Dec 31, 2023 | $165.32M | -70.6% |
| Q3 FY2023 | Sep 30, 2023 | $219.70M | -63.0% |
| Q2 FY2023 | Jun 30, 2023 | $325.07M | -47.3% |
| Q1 FY2023 | Mar 31, 2023 | $440.57M | -32.7% |
| Q4 FY2022 | Dec 31, 2022 | $562.51M | -22.1% |
| Q3 FY2022 | Sep 30, 2022 | $593.91M | -23.1% |
| Q2 FY2022 | Jun 30, 2022 | $617.13M | -26.1% |
| Q1 FY2022 | Mar 31, 2022 | $654.31M | -25.4% |
| Q4 FY2021 | Dec 31, 2021 | $721.92M | -23.1% |
| Q3 FY2021 | Sep 30, 2021 | $772.40M | -19.9% |
| Q2 FY2021 | Jun 30, 2021 | $835.36M | -6.6% |
| Q1 FY2021 | Mar 31, 2021 | $877.10M | +50.1% |
| Q4 FY2020 | Dec 31, 2020 | $938.55M | +47.2% |
| Q3 FY2020 | Sep 30, 2020 | $963.71M | +50.5% |
| Q2 FY2020 | Jun 30, 2020 | $894.66M | +32.8% |
| Q1 FY2020 | Mar 31, 2020 | $584.28M | +7.7% |
| Q4 FY2019 | Dec 31, 2019 | $637.52M | +8.0% |
| Q3 FY2019 | Sep 30, 2019 | $640.22M | +5.5% |
| Q2 FY2019 | Jun 30, 2019 | $673.48M | +7.3% |
| Q1 FY2019 | Mar 31, 2019 | $542.73M | +93.0% |
| Q4 FY2018 | Dec 31, 2018 | $590.40M | +105.9% |
| Q3 FY2018 | Sep 30, 2018 | $606.60M | +124.8% |
| Q2 FY2018 | Jun 30, 2018 | $627.73M | +121.8% |
| Q1 FY2018 | Mar 31, 2018 | $281.17M | +91.5% |
| Q4 FY2017 | Dec 31, 2017 | $286.74M | +81.6% |
| Q3 FY2017 | Sep 30, 2017 | $269.79M | +63.5% |
| Q2 FY2017 | Jun 30, 2017 | $282.99M | +56.4% |
| Q1 FY2017 | Mar 31, 2017 | $146.81M | – |
| Q4 FY2016 | Dec 31, 2016 | $157.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $164.98M | – |
| Q2 FY2016 | Jun 30, 2016 | $180.91M | – |
See a number that looks wrong?